|
|
Article: The Medicines Company Announces Publication of First Ever Randomized Clinical Trial Assessing Replacement for Heparin in CABG Surgery.
- Article from:
- Business Wire
- Article date:
- March 4, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
PARSIPPANY, N.J.--(BUSINESS WIRE)--March 4, 2004
The Medicines Company (Nasdaq: MDCO):
-- Annals of Thoracic Surgery reports bivalirudin (Angiomax(R))
anticoagulation feasible in off-pump coronary artery bypass
graft surgery
-- Patients in bivalirudin group had better graft flow at 90-days